Bristol-Myers Squibb (BMY) July 26 weekly 44.5 straddle priced into quarter results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Bristol-Myers Squibb (BMY) stock gains after raising full-year guidance
July 26, 2024 7:51 AM EDTBristol-Myers Squibb (NYSE: BMY) shares rallied more than 5% premarket Friday as the company reported a robust second quarter, surpassing Wall Street's expectations for both earnings and revenue, and raised its full-year guidance.
The pharmaceutical giant posted adjusted earnings per share (EPS) of $2.07, significantly higher than the analyst estimate of $1.64. Revenue for the quarter was also strong at $12.2 billion, beating the consensus estimate of $11.52 billion and marking a 9% increase from the same quarter last year, or an 11% rise adjusting for foreign exchange.
The company's performance was propelled by its Growth Portfolio, which saw... More
